219 related articles for article (PubMed ID: 21539473)
1. Low molecular weight inhibitors of Prolyl Oligopeptidase: a review of compounds patented from 2003 to 2010.
López A; Tarragó T; Giralt E
Expert Opin Ther Pat; 2011 Jul; 21(7):1023-44. PubMed ID: 21539473
[TBL] [Abstract][Full Text] [Related]
2. Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders.
Männisto PT; Venäläinen J; Jalkanen A; García-Horsman JA
Drug News Perspect; 2007 Jun; 20(5):293-305. PubMed ID: 17878957
[TBL] [Abstract][Full Text] [Related]
3. Prolyl oligopeptidase and its role in the organism: attention to the most promising and clinically relevant inhibitors.
Babkova K; Korabecny J; Soukup O; Nepovimova E; Jun D; Kuca K
Future Med Chem; 2017 Jun; 9(10):1015-1038. PubMed ID: 28632451
[TBL] [Abstract][Full Text] [Related]
4. Translational research on prolyl oligopeptidase inhibitors: the long road ahead.
Lambeir AM
Expert Opin Ther Pat; 2011 Jul; 21(7):977-81. PubMed ID: 21679099
[TBL] [Abstract][Full Text] [Related]
5. On the role of prolyl oligopeptidase in health and disease.
García-Horsman JA; Männistö PT; Venäläinen JI
Neuropeptides; 2007 Feb; 41(1):1-24. PubMed ID: 17196652
[TBL] [Abstract][Full Text] [Related]
6. Fluorescence resonance energy transfer (FRET) peptides and cycloretro-inverso peptides derived from bradykinin as substrates and inhibitors of prolyl oligopeptidase.
Gorrão SS; Hemerly JP; Lima AR; Melo RL; Szeltner Z; Polgár L; Juliano MA; Juliano L
Peptides; 2007 Nov; 28(11):2146-54. PubMed ID: 17904692
[TBL] [Abstract][Full Text] [Related]
7. Identification by 19F NMR of traditional Chinese medicinal plants possessing prolyl oligopeptidase inhibitory activity.
Tarragó T; Frutos S; Rodriguez-Mias RA; Giralt E
Chembiochem; 2006 May; 7(5):827-33. PubMed ID: 16628753
[TBL] [Abstract][Full Text] [Related]
8. Benzimidazolium salts as small, nonpeptidic and BBB-permeable human prolyl oligopeptidase inhibitors.
Tarragó T; Masdeu C; Gómez E; Isambert N; Lavilla R; Giralt E
ChemMedChem; 2008 Oct; 3(10):1558-65. PubMed ID: 18792035
[TBL] [Abstract][Full Text] [Related]
9. Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors.
Venäläinen JI; Garcia-Horsman JA; Forsberg MM; Jalkanen A; Wallén EA; Jarho EM; Christiaans JA; Gynther J; Männistö PT
Biochem Pharmacol; 2006 Feb; 71(5):683-92. PubMed ID: 16405869
[TBL] [Abstract][Full Text] [Related]
10. Molecular dynamics study of prolyl oligopeptidase with inhibitor in binding cavity.
Kaszuba K; Rog T; St Pierre JF; Mannisto PT; Karttunen M; Bunker A
SAR QSAR Environ Res; 2009 Oct; 20(7-8):595-609. PubMed ID: 20024801
[TBL] [Abstract][Full Text] [Related]
11. Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor.
Tarragó T; Kichik N; Claasen B; Prades R; Teixidó M; Giralt E
Bioorg Med Chem; 2008 Aug; 16(15):7516-24. PubMed ID: 18650094
[TBL] [Abstract][Full Text] [Related]
12. The natural product berberine is a human prolyl oligopeptidase inhibitor.
Tarrago T; Kichik N; Seguí J; Giralt E
ChemMedChem; 2007 Mar; 2(3):354-9. PubMed ID: 17295371
[TBL] [Abstract][Full Text] [Related]
13. Targeted Covalent Inhibition of Prolyl Oligopeptidase (POP): Discovery of Sulfonylfluoride Peptidomimetics.
Guardiola S; Prades R; Mendieta L; Brouwer AJ; Streefkerk J; Nevola L; Tarragó T; Liskamp RMJ; Giralt E
Cell Chem Biol; 2018 Aug; 25(8):1031-1037.e4. PubMed ID: 29779956
[TBL] [Abstract][Full Text] [Related]
14. Peptide POP inhibitors for the treatment of the cognitive symptoms of schizophrenia.
López A; Mendieta L; Prades R; Royo S; Tarragó T; Giralt E
Future Med Chem; 2013 Sep; 5(13):1509-23. PubMed ID: 24024944
[TBL] [Abstract][Full Text] [Related]
15. Modulating the selectivity of inhibitors for prolyl oligopeptidase inhibitors and fibroblast activation protein-α for different indications.
Plescia J; Hédou D; Pousse ME; Labarre A; Dufresne C; Mittermaier A; Moitessier N
Eur J Med Chem; 2022 Oct; 240():114543. PubMed ID: 35797897
[TBL] [Abstract][Full Text] [Related]
16. Hunting for peptide substrates of prolyl oligopeptidase: classical versus non-classical bioactive peptides.
Tenorio-Laranga J; Männistö PT; García-Horsman JA
CNS Neurol Disord Drug Targets; 2011 May; 10(3):319-26. PubMed ID: 21222622
[TBL] [Abstract][Full Text] [Related]
17. Investigation of novel chemical scaffolds targeting prolyl oligopeptidase for neurological therapeutics.
Kumar R; Parameswaran S; Bavi R; Baek A; Son M; Rampogu S; Park C; Lee G; Zeb A; Parate S; Rana RM; Lee KW
J Mol Graph Model; 2019 May; 88():92-103. PubMed ID: 30665156
[TBL] [Abstract][Full Text] [Related]
18. Calpain inhibitors: a survey of compounds reported in the patent and scientific literature.
Donkor IO
Expert Opin Ther Pat; 2011 May; 21(5):601-36. PubMed ID: 21434837
[TBL] [Abstract][Full Text] [Related]
19. Patent-related survey on new monoamine oxidase inhibitors and their therapeutic potential.
Carradori S; Secci D; Bolasco A; Chimenti P; D'Ascenzio M
Expert Opin Ther Pat; 2012 Jul; 22(7):759-801. PubMed ID: 22702491
[TBL] [Abstract][Full Text] [Related]
20. A new side opening on prolyl oligopeptidase revealed by electron microscopy.
Tarragó T; Martín-Benito J; Sabidó E; Claasen B; Madurga S; Gairí M; Valpuesta JM; Giralt E
FEBS Lett; 2009 Oct; 583(20):3344-8. PubMed ID: 19782684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
